Trial Profile
A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2022
Price :
$35
*
At a glance
- Drugs Vosoritide (Primary)
- Indications Achondroplasia
- Focus Adverse reactions
- Sponsors BioMarin Pharmaceutical
- 30 Jun 2022 Planned End Date changed from 1 Oct 2022 to 1 Feb 2028.
- 30 Jun 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Dec 2027.
- 04 Jul 2019 Results evaluating use of vosoritide in children with achondroplasia from study 202, 205 and 901 wee published in the New England Journal of Medicine.